Williams Jones & Associates LLC decreased its position in Colgate-Palmolive (NYSE:CL) by 1.0% in the 1st quarter, HoldingsChannel reports. The fund owned 260,860 shares of the company’s stock after selling 2,580 shares during the quarter. Williams Jones & Associates LLC’s holdings in Colgate-Palmolive were worth $17,879,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Capital Financial Planning LLC bought a new position in Colgate-Palmolive during the fourth quarter valued at about $27,000. Parisi Gray Wealth Management grew its position in Colgate-Palmolive by 365.3% during the fourth quarter. Parisi Gray Wealth Management now owns 470 shares of the company’s stock valued at $28,000 after buying an additional 369 shares during the period. Portfolio Solutions LLC bought a new position in Colgate-Palmolive during the fourth quarter valued at about $30,000. WP Advisors LLC bought a new position in Colgate-Palmolive during the first quarter valued at about $34,000. Finally, Lindbrook Capital LLC bought a new position in Colgate-Palmolive during the fourth quarter valued at about $36,000. Hedge funds and other institutional investors own 75.66% of the company’s stock.
In other news, VP Justin Skala sold 92,643 shares of the stock in a transaction dated Tuesday, May 7th. The shares were sold at an average price of $70.78, for a total value of $6,557,271.54. Following the sale, the vice president now directly owns 163,653 shares of the company’s stock, valued at $11,583,359.34. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Ian M. Cook sold 16,000 shares of the stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $66.72, for a total transaction of $1,067,520.00. Following the completion of the sale, the chief executive officer now directly owns 1,146,793 shares in the company, valued at $76,514,028.96. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 354,711 shares of company stock worth $25,087,935. Insiders own 1.14% of the company’s stock.
Several equities analysts recently weighed in on the stock. UBS Group increased their price target on shares of Colgate-Palmolive from $71.00 to $75.00 and gave the company a “buy” rating in a research report on Friday, March 29th. Zacks Investment Research lowered shares of Colgate-Palmolive from a “hold” rating to a “sell” rating in a research report on Tuesday, April 23rd. JPMorgan Chase & Co. upgraded shares of Colgate-Palmolive from an “underweight” rating to a “neutral” rating and increased their price target for the company from $62.00 to $70.00 in a research report on Monday, April 29th. Jefferies Financial Group increased their price target on shares of Colgate-Palmolive from $61.00 to $73.00 and gave the company an “in-line” rating in a research report on Monday, April 29th. They noted that the move was a valuation call. Finally, ValuEngine upgraded shares of Colgate-Palmolive from a “hold” rating to a “buy” rating in a research report on Monday, May 13th. One analyst has rated the stock with a sell rating, twelve have given a hold rating and five have assigned a buy rating to the company. Colgate-Palmolive currently has a consensus rating of “Hold” and a consensus target price of $70.13.
NYSE CL traded up $0.03 during trading on Tuesday, hitting $73.06. 125,781 shares of the company’s stock traded hands, compared to its average volume of 3,005,450. The company has a market cap of $63.52 billion, a PE ratio of 24.58, a price-to-earnings-growth ratio of 4.84 and a beta of 0.79. Colgate-Palmolive has a 12-month low of $57.41 and a 12-month high of $74.14. The company has a quick ratio of 0.74, a current ratio of 1.07 and a debt-to-equity ratio of 32.25.
Colgate-Palmolive (NYSE:CL) last released its quarterly earnings data on Friday, April 26th. The company reported $0.67 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.66 by $0.01. The business had revenue of $3.88 billion for the quarter, compared to the consensus estimate of $3.86 billion. Colgate-Palmolive had a net margin of 15.08% and a negative return on equity of 3,730.37%. The company’s revenue was down 2.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.74 earnings per share. As a group, equities research analysts anticipate that Colgate-Palmolive will post 2.84 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, May 15th. Shareholders of record on Friday, April 19th were issued a dividend of $0.43 per share. The ex-dividend date was Wednesday, April 17th. This is an increase from Colgate-Palmolive’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a yield of 2.35%. Colgate-Palmolive’s dividend payout ratio is 57.91%.
ILLEGAL ACTIVITY NOTICE: This news story was originally posted by Equities Focus and is the property of of Equities Focus. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.equitiesfocus.com/2019/06/11/colgate-palmolive-nysecl-stake-lessened-by-williams-jones-associates-llc.html.
Colgate-Palmolive Company Profile
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. It offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; and personal care products, such as liquid hand soaps, bar soaps, shower gels, deodorants and antiperspirants, skin care products, and shampoos and conditioners.
Further Reading: Compound Interest and Why It Matters When Investing
Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive (NYSE:CL).
Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.